Inaxaplin
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Apr 30, 2020 (NCT04340362)
Timeline
Indications
Mechanism of action
- Apolipoprotein L1INHIBITOR
inhibitor - APOL1
Chemistry & pharmacology
Loading structure…
SMILES
O=C(CCc1c(-c2ccc(F)cc2)[nH]c2c(F)cc(F)cc12)N[C@@H]1C(=O)NC[C@H]1O- Mol. weight
- 417.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5083170 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06794996 | Phase 2 | Feb 4, 2025 | Vertex |
| NCT06529796 | Phase 1 | Aug 2, 2024 | Vertex |
| NCT05955872 | Phase 1 | Jul 19, 2023 | Vertex |
| NCT05865171 | Phase 1 | Jun 12, 2023 | Vertex |
| NCT05312879 | Phase 2/Phase 3 (Phase 3) | Mar 30, 2022 | Vertex |
| NCT04340362 | Phase 2 | Apr 30, 2020 | Vertex |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vertex | For profit | 6 | 6 | 3 | 2020 |
1 organizations
Page 1 / 1